Loading...
ACER logo

Acer Therapeutics Inc.OTCPK:ACER Stock Report

Market Cap US$19.7m
Share Price
n/a
My Fair Value
n/a
1Y-30.0%
7D-5.4%
1D
Portfolio Value
​
View

Acer Therapeutics Inc.

OTCPK:ACER Stock Report

Market Cap: US$19.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Acer Therapeutics (ACER) Stock Overview

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. More details

ACER fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Rewards

Earnings are forecast to grow 66.22% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Negative shareholders equity

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

+ 2 more risks

ACER Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Acer Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Acer Therapeutics
Historical stock prices
Current Share PriceUS$0.80
52 Week HighUS$4.56
52 Week LowUS$0.55
Beta0.44
1 Month Change-2.73%
3 Month Change21.88%
1 Year Change-30.04%
3 Year Change-70.42%
5 Year Change-96.75%
Change since IPO-91.99%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 05

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Acer Therapeutics (NASDAQ:ACER) said on Wednesday it was expanding ACER-801 into a new indication, to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder. (ACER) is trading 3.5% higher premarket. In a study conducted in thousands of genes that were activated in the brains of mice following fear conditioning events showed the drug was able to block fear memory consolidation shortly after exposure to a trauma. ACER-801 is a non-hormonal drug designed as a selective non-peptide neurokinin 3 receptor (NK3R) antagonist. "While the role of the NK3R pathway in the hypothalamus to manage thermoregulation is well-established in clinical trials, this opportunity explores an entirely different mechanism of action for the drug. We look forward to presenting our clinical development plan for ACER-801 for the reduction of frequency and severity of PTSD in the near future," the company said. Acute stress disorder refers to the body’s immediate response to trauma, whereas PTSD is defined as the long-term effects of trauma. The company is also developing the drug for induced Vasomotor Symptoms, which is hot flashes, flushing, and night sweats — that tend to occur in or around menopause.
Seeking Alpha • Aug 12

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

The European Commission granted orphan medicinal product designation to Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics' (OTCQB:RLFTF) (OTCQB:RLFTY) ACER-001 (sodium phenylbutyrate) to treat patients with Maple Syrup Urine Disease (MSUD). ACER-001 was had received the U.S. Food and Drug Administration's (FDA) orphan drug designation for MSUD in 2014, the companies said in an Aug. 12 press release. MSUD is a rare genetic metabolic disorder characterized by deficiency of an enzyme complex which is required to break down certain amino acids in the body. In the EU, the orphan drug status is granted to therapies aimed at treating or preventing a serious or life-threatening disease which affects not more than five in 10K people in the EU. The designation has benefits, including up to 10 years of market exclusivity for the product, if approved. ACER +6.76% to $1.58 premarket Aug. 12
Seeking Alpha • Jul 28

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics (NASDAQ:ACER) and partner Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the companies' resubmission of their new drug application for their ACER-001 treatment for patients with urea cycle disorders. The FDA designated the new drug application (NDA) as a class 2 resubmission and said it would review the application by Jan. 15, 2023, or the so-called Prescription Drug User Fee Act date. Despite the news, ACER stock had fallen 4.2% to $1.37 in premarket trading. The FDA's acceptance of the NDA comes 10 days after ACER and RLFTF resubmitted the application. The NDA had been initially declined by the FDA in June as the agency's field investigator had been unable to complete inspection of ACER's third-party contract packaging manufacturer.
Seeking Alpha • Jul 18

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Newton, Massachusetts-based Acer Therapeutics (NASDAQ:ACER) announced on Monday that the company resubmitted its New Drug Application (NDA) seeking FDA approval of ACER-001 oral suspension for the treatment of patients with urea cycle disorders (UCDs). Also known as sodium phenylbutyrate, ACER-001 is undergoing studies as a treatment for various inborn errors of metabolism such as UCDs. In June, Acer (ACER) announced that the FDA issued a Complete Response Letter (CRL), rejecting the marketing approval of the drug, citing the need for satisfactory inspection of its third-party contract packaging manufacturer. In the resubmission, the company has informed the FDA that the contract manufacturer in question is ready for inspections. In addition to labeling and other standard updates to the original filing, the resubmitted NDA included the nonclinical info that the FDA requested but categorized as “not an approvability issue” in the CRL. A decision on the acceptance of the NDA is expected within 14 calendar days of the submission. Last month, the shares of Acer (ACER) and its partner Relief Therapeutics (OTCQB:RLFTF) fell on the announcement of FDA rejection of ACER-001.
Analysis Article • Feb 11

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 31

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification regarding potential acceptance for filing from the FDA approximately 60 days after NDA submission and subsequent substantive review. If approved, Acer could launch ACER-001 in mid-2022. Other than UCDs, Acer is developing therapies for MSUD, iVMS, vEDS, and infectious diseases. All these diseases have a market that is niche and untapped, characterized by low competition. Assuming a base case revenue of $40 million in 2022 and a P/S ratio of 5.0x, the company’s intrinsic value would be ~$122 million or $8.70 per share, indicating an upside close to 3.5x.
Analysis Article • May 20

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 25

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Shareholder Returns

ACERUS PharmaceuticalsUS Market
7D-5.4%3.3%1.8%
1Y-30.0%44.6%28.4%

Return vs Industry: ACER underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.

Return vs Market: ACER underperformed the US Market which returned 15.2% over the past year.

Price Volatility

Is ACER's price volatile compared to industry and market?
ACER volatility
ACER Average Weekly Movement32.3%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: ACER's share price has been volatile over the past 3 months.

Volatility Over Time: ACER's weekly volatility has increased from 23% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199130Chris Schellingwww.acertx.com

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company’s pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder.

Acer Therapeutics Inc. Fundamentals Summary

How do Acer Therapeutics's earnings and revenue compare to its market cap?
ACER fundamental statistics
Market capUS$19.68m
Earnings (TTM)-US$38.76m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.5x
P/E Ratio

Is ACER overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACER income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$38.76m
Earnings-US$38.76m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-96.4%

How did ACER perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/20 02:33
End of Day Share Price 2023/11/17 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acer Therapeutics Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Constantine DavidesD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.